Metabolomics and the great obstetrical syndromes – GDM, PET, and IUGR

Gestational diabetes mellitus, intrauterine growth restriction, and preeclamptic toxemia are common pregnancy complications that can have detrimental effects on morbidity and mortality of the mother and fetus as well as long-term health outcomes. Although they are distinct conditions, they may occur...

Full description

Saved in:
Bibliographic Details
Published in:Best practice & research. Clinical obstetrics & gynaecology 2015-02, Vol.29 (2), p.156-164
Main Authors: Dessì, Angelica, MD, Marincola, Flamina Cesare, PhD, Fanos, Vassilios, MD
Format: Article
Language:English
Subjects:
Biomarkers - metabolism
Diabetes, Gestational - diagnosis
Diabetes, Gestational - etiology
Diabetes, Gestational - metabolism
Diabetes, Gestational - prevention & control
Female
Fetal Growth Retardation - diagnosis
Fetal Growth Retardation - etiology
Fetal Growth Retardation - metabolism
Fetal Growth Retardation - prevention & control
GDM
Humans
IUGR
Metabolomics
newborn
Obstetrics and Gynecology
PET
Pre-Eclampsia - diagnosis
Pre-Eclampsia - etiology
Pre-Eclampsia - metabolism
Pre-Eclampsia - prevention & control
Pregnancy
Prenatal Diagnosis
Risk Factors
Syndrome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gestational diabetes mellitus, intrauterine growth restriction, and preeclamptic toxemia are common pregnancy complications that can have detrimental effects on morbidity and mortality of the mother and fetus as well as long-term health outcomes. Although they are distinct conditions, they may occur together and are often considered together as they share a common etiology of inadequate placental perfusion. The discovery and study of preventative treatments is hampered by a lack of effective screening tools to accurately identify women at the highest risk of disease. Metabolomics, an omic science, is the global quantitative assessment of endogenous metabolites within a biological system. It has proven to be a rapid approach in the identification of biomarkers predictive of the outcome of a pathological condition and the individual's response to a pharmacological treatment. We review the current and potential applications of metabolomics in maternal–fetal medicine, focusing on its use as a biomarker for great obstetrical syndromes diagnosis.
ISSN:1521-6934
1532-1932
DOI:10.1016/j.bpobgyn.2014.04.023